Accordingly, regulators of actomyosin contractility and Rho-ROCK signaling in cancer cells have become the main target of drugs that target cell motility (“migrastatics”) and showed promising effects both in vitro and in vivo in a variety of cancer types including lung, breast and prostate cancer5,6. Here, RHO is linked to cancer.